SEP 18, 2018 9:20 PM PDT

More Challenges in Immunotherapeutic Developments

WRITTEN BY: Nouran Amin

Image via BioTech Stocks

Fighting disease using the immune system is the body’s most prized possession and it does so by utilizing immunotherapy. However, a discovery by researchers at the University of Notre Dame has found a challenge in creating molecules for immunotherapy for the purpose of drug development. More specifically, researchers found two different peptide antigens that react with one T-cell receptor (TCR) according to the study published in Nature Chemical Biology.

"Essentially, we discovered that T-cell receptors can be much more cross-reactive than we previously envisioned, which is somewhat concerning for the entire field," explains lead author Timothy Riley.

Considered a subtype of white blood cells, T cells are responsible for detecting any changes in our immune health. However, they do not always detect cancer cells; ignoring their potential threat. For T-cell immunotherapy, targeted cells are altered to contain receptors that allow T cell recognition of ‘dangerous’ cells. Although this particular immunotherapeutic is effective, it can also attack and destroy healthy cells. Thus, scientists have been seeking to predict reactivity and to ensure that T cells recognize only the targeted cells by delving deeper into the TCR analysis.

To learn more about T-cells and TCR, watch the video below:

"We thought the TCR was ignoring small differences (in the highly charged target) a little bit, and simply found things similar to recognize," says Brian Baker, the John A. Zahm, C.S.C., Professor of Structural Biology and chair of the Department of Chemistry and Biochemistry. "But that was wrong. We discovered that this peptide moved and adapted in order for the receptor to bind, in a way that no one had seen before."

These two different proteins, or peptide antigens, worked at the same level for binding specificity with DMF5, where they stimulated the receptor and induced an immune response. "It doesn't really matter how it works, as long as binding occurs," Riley said.

The research findings have advanced our understanding of how to develop immunotherapies in the realm of drug discovery, but remains a hurdle to overcome. "What's significant is that people try to make predictions for developing these models for therapy, and about the kinds of ways you can recognize targets," explains Riley. "Now that we have great examples of a T-cell receptor recognizing multiple peptide antigens that are structurally different, we can use them to build hypotheses and test predictions."

Source: University of Notre Dame

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 09, 2019
Drug Discovery & Development
DEC 09, 2019
Could the diabetic drug 'metformin' extend a healthy lifespan?
The most commonly prescribed diabetic medication for the Type 2 condition is ‘Metformin’—a drug with a mysterious mechanism of action but...
DEC 19, 2019
Technology
DEC 19, 2019
Can a 'Lemon' help develop new drugs?
Although artificial intelligence has many advantages in the drug discovery process, challenges still remain--one being the ability for machine learning to ...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
Researchers Grow Psilocybin from E. Coli Bacteria
Previously considered to be narcotic, and under tight regulation as an illicit drug for decades, research from recent years on the possible medicinal prope...
JAN 21, 2020
Cannabis Sciences
JAN 21, 2020
Medical Marijuana Ineffective for Long Term Pain Management
Medicinal cannabis may not as effective as once thought as a solution for sleep problems for those with chronic pain in the long run, according to new find...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
FEB 10, 2020
Drug Discovery & Development
FEB 10, 2020
Drug Prevents Coronavirus in Monkeys
An antiviral drug successfully prevented Middle East respiratory syndrome coronavirus (MERS-CoV) in infected rhesus macaques. The drug, Remdesivir, was adm...
Loading Comments...